AxoGlia Therapeutics SA is a biopharmaceutical company which drives the development of innovative therapeutic approach with stem/progenitor cell differentiation capacities for indications in neurology and cancer.

AxoGlia was set up to develop and commercialize the expertise gained in neurotrophic factors biomimetic and regenerative medicine for treating neurodegenerative diseases such as Multiple Sclerosis and Parkinson’s disease.

AxoGlia has built-up a portfolio of neurogenic and anti-inflammatory molecules targeting brain repair. These therapeutic candidates are optimized to improve functional integration and survival of new mature neurons.

AxoGlia has developed strong research collaboration with Professor Rudi Balling of the Luxembourg Centre for Systems Biomedicine to identify novel therapeutic targets for Parkinson’s disease.